A. Cancer statistics, 2016. CA Cancer J Clin. January–February 2016;66(1):7–30.
RD. Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. Cancer. April 15, 1999;85(8):1686–1693.
et al. Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus
(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst
. February 6, 2013;105(3):175–201.
JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973–2000. Cancer. July 15, 2004;101(2):281–288.
LL. Changing patterns of anal canal carcinoma in the United States. J Clin Oncol. April 20, 2013;31(12):1569–1575.
HR. Surgical anatomy of the anal canal with special reference to the surgical importance of the internal sphincter and conjoint longitudinal muscle. Ann R Coll Surg Engl. August 1956;19(2):88–114.
et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. October 2012;136(10):1266–1297.
et al. Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men. Int J Cancer. March 1, 2014;134(5):1147–1155.
American Joint Committee on Cancer. American Joint Committee on Cancer Staging Manual, 7th Edition. New York, NY: Springer; 2010.
EA. Molecular virology and epidemiology of human papillomavirus
and cervical cancer. Cancer Epidemiol Biomarkers Prev
. June 1995;4(4):415–428.
FT, World Health Organization, International Agency for Research on Cancer.
World Health Organizaton Classification of Human Tumours of the Digestive System. Lyon: IARC Press; 2000.
International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Human papillomaviruses, Vol. 90. Geneva: WHO Press; 2007:1–636.
S. Prevalence and type distribution of human papillomavirus
in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer
. April 1, 2009;124(7):1626–1636.
JS. Human papillomavirus
type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer
. May 15, 2009;124(10):2375–2383.
et al. Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men. J Infect Dis. December 2013;208(11):1768–1775.
RK. Risk factors for anal cancer: results of a population-based case--control study. Cancer Causes Control. November 2003;14(9):837–846.
B, van den Brule
et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. November 6, 1997;337(19):1350–1358.
et al. Human papillomavirus
, smoking, and sexual practices in the etiology of anal cancer. Cancer
. July 15, 2004;101(2):270–280.
et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med. October 15, 1987;317(16):973–977.
et al. Anal human papillomavirus
infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol
. May 2012;13(5):487–500.
AG. The epidemiology of anal human papillomavirus
infection among women and men having sex with women. Sex Health
. December 2012;9(6):538–546.
F, de Pokomandy
EL. Epidemiology, natural history and risk factors for anal intraepithelial neoplasia. Sex Health. December 2012;9(6):547–555.
TM, Da Costa
et al. High prevalence of anal human papillomavirus
infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med
. March 18, 2003;138(6):453–459.
et al. Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. J Natl Cancer Inst
. June 15, 2005;97(12):896–905.
JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. September 20, 2000;92(18):1500–1510.
et al. Sequential acquisition of human papillomavirus
(HPV) infection of the anus and cervix: the Hawaii HPV Cohort Study. J Infect Dis
. May 1, 2010;201(9):1331–1339.
et al. Acquisition of anal human papillomavirus
(HPV) infection in women: the Hawaii HPV Cohort study. J Infect Dis
. April 1, 2008;197(7):957–966.
et al. Prevalence of and risk factors for anal human papillomavirus
infection among young healthy women in Costa Rica. J Infect Dis
. October 1, 2012;206(7):1103–1110.
et al. Anal HPV prevalence and associated factors among HIV-seropositive men under antiretroviral treatment in Brazil. J Acquir Immune Defic Syndr. August 2011;57(suppl 3):S217–S224.
et al. Prevalence of and risk factors for anal human papillomavirus
infection in heterosexual men. J Infect Dis
. June 15, 2008;197(12):1676–1684.
AG, Carvalho da Silva
et al. Age-specific prevalence of and risk factors for anal human papillomavirus
(HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study. J Infect Dis
. January 1, 2011;203(1):49–57.
et al. Anal human papillomavirus
infection in women and its relationship with cervical infection. Cancer Epidemiol Biomarkers Prev
. November 2005;14(11 pt 1):2550–2556.
AE, van Leeuwen
CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. July 7, 2007;370(9581):59–67.
S. Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978–2005. Int J Cancer. August 1, 2010;127(3):675–684.
et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. May 4, 2011;103(9):753–762.
et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. April 2012;54(7):1026–1034.
et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. August 1, 2008;48(4):491–499.
TM. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS. March 26, 1998;12(5):495–503.
EA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst. August 19, 2009;101(16):1120–1130.
S. High rates of anal dysplasia in HIV-infected men who have sex with men, women, and heterosexual men. AIDS. January 14, 2014;28(2):215–222.
et al. HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin Infect Dis
. May 2011;52(9):1174–1181.
EA. Impact of the HIV epidemic on the incidence rates of anal cancer in the United States. J Natl Cancer Inst. October 17, 2012;104(20):1591–1598.
et al. Prevalence of anal intraepithelial neoplasia defined by anal cytology screening and high-resolution anoscopy in a primary care population of HIV-infected men and women. Dis Colon Rectum. April 2011;54(4):433–441.
et al. High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus
vaccine. HIV Clin Trials
. March–April 2013;14(2):75–79.
et al. Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors. AIDS. July 11, 2007;21(11):1457–1465.
et al. Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study. Am J Epidemiol. September 15, 2013;178(6):877–884.
et al. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS. February 20, 2010;24(4):535–543.
et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS
. June 19, 2008;22(10):1203–1211.
B, Schmeltz Sogaard
S. Risk of human papillomavirus-related cancers among kidney transplant recipients and patients receiving chronic dialysis—an observational cohort study. BMC Nephrol
EA. HPV-related cancers after solid organ transplantation in the United States. Am J Transplant. December 2013;13(12):3202–3209.
JM. Human papillomavirus
infection and anal dysplasia in renal transplant recipients. Br J Surg
. November 2010;97(11):1716–1721.
et al. Prevalence of anal human papillomavirus
infection and intraepithelial neoplasia in renal allograft recipients. Br J Surg
. March 1994;81(3):365–367.
et al. Initial prevalence of anal human papilloma virus infection in liver transplant recipients. Transpl Int. August 2014;27(8):816–823.
A. Prevalence of anal HPV infection in solid-organ transplant patients prior to immunosuppression. Transpl Int. August 2004;17(7):366–369.
S. Subsequent malignant neoplasms after hematopoietic cell transplantation. Biol Blood Marrow Transplant. January 2012;18(1 suppl):S139–S150.
et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood. January 6, 2011;117(1):316–322.
AG, Carvalho da Silva
et al. Six-month incidence, persistence, and factors associated with persistence of anal human papillomavirus
in men: the HPV in men study. J Infect Dis
. December 1, 2011;204(11):1711–1722.
M. Tobacco smoking as a risk factor in anal carcinoma: an antiestrogenic mechanism?
J Natl Cancer Inst. April 21, 1999;91(8):708–715.
et al. Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women. AIDS. January 2, 2009;23(1):59–70.
R, Tinnirello Mde
L. Anal intraepithelial lesions in women with human papillomavirus-related disease. J Low Genit Tract Dis. October 2012;16(4):454–459.
P. Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol. April 2007;8(4):311–316.
H. Papillomaviruses in human cancers. Proc Assoc Am Phys. November–December 1999;111(6):581–587.
CS. HPV-16 E2 gene disruption and sequence variation in CIN 3 lesions and invasive squamous cell carcinomas of the cervix: relation to numerical chromosome abnormalities. Mol Pathol. August 2000;53(4):201–206.
T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Science. October 2007;98(10):1505–1511.
PF. Dominant role of HPV16 E7 in anal carcinogenesis. Virology. December 20, 2011;421(2):114–118.
et al. Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus
type 16 in cervical keratinocytes. Cancer Research
. February 15, 2004;64(4):1359–1368.
et al. Biological activity of probable/possible high-risk human papillomavirus
types in cervical cancer. Int J Cancer
. January 1, 2013;132(1):63–71.
TA. p16 is superior to ProEx C in identifying high-grade squamous intraepithelial lesions (HSIL) of the anal canal. Am J Surg Pathol
. May 2013;37(5):659–668.
et al. Expression of proliferative biomarkers in anal intraepithelial neoplasia of HIV-positive men. J Am Acad Dermatol. September 2010;63(3):490–498.
HL. Expression of p16, Rb, and p53 proteins in squamous cell carcinomas of the anorectal region harboring human papillomavirus
DNA. Mod Pathol
. July 2003;16(7):692–699.
et al. Signature patterns of human papillomavirus
type 16 in invasive anal carcinoma. Hum Pathol
. June 2013;44(6):992–1002.
PF. A mouse model for human anal cancer. Cancer Prevention Research. December 2010;3(12):1534–1541.
et al. TGF-beta receptor I conditional knockout mice develop spontaneous squamous cell carcinoma. Cell Cycle
. June 1, 2007;6(11):1360–1366.
AB. Inhibition of mTOR reduces anal carcinogenesis in transgenic mouse model. PloS One
et al. Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma. IInt J Cancer. December 15, 2007;121(12):2668–2673.
B. Recurrent deletions of chromosomes 11q and 3p in anal canal carcinoma. Int J Cancer. May 15, 1987;39(5):595–598.
K, du Manoir
et al. A recurrent pattern of chromosomal aberrations and immunophenotypic appearance defines anal squamous cell carcinomas. Br J Cancer
et al. Molecular biology of squamous cell carcinoma of the anus: a comparison of HIV-positive and HIV-negative patients. J Gastrointest Surg. December 2004;8(8):1024–1030; discussion 1031.
JM. Detection of genetic changes in anal intraepithelial neoplasia (AIN) of HIV-positive and HIV-negative men. J Acquir Immune Defic Syndr. March 1, 2001;26(3):256–262.
et al. High-resolution analysis of genomic alterations and human papillomavirus
integration in anal intraepithelial neoplasia. J Acquir Immune Defic Syndr
. October 1, 2005;40(2):182–189.
P. Molecular biology of squamous cell carcinoma of the anus. Br J Surg
. May 2006;93(5):531–538.
SB. The epigenomics of cancer. Cell. February 23, 2007;128(4):683–692.
et al. DNA methylation in anal intraepithelial lesions and anal squamous cell carcinoma. Clin Cancer Res. September 15, 2005;11(18):6544–6549.
et al. DNA methylation profiling across the spectrum of HPV-associated anal squamous neoplasia. PloS One
et al. Epigenomic characterization of locally advanced anal cancer: an RTOG 98-11 specimen study. Dis Colon Rectum. In Press.
et al. Gene expression reveals two distinct groups of anal carcinomas with clinical implications. Br J Cancer. April 8 2008;98(7):1264–1273.
et al. Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review. Br J Cancer. December 7, 2010;103(12):1858–1869.
MA. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma. Clin Cancer Res. December 15, 2003;9(17):6489–6496.
BJ. Prognostic role of p53 protein expression in epidermoid carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. September 1, 1999;45(2):309–314.
et al. p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy. Radiother Oncol. October 2013;109(1):146–151.
et al. Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci. April 28, 2009.
B. Prognostic significance of Cyclin A in epidermoid anal cancer. Oncol Rep. September 2006;16(3):443–449.
G. Reduced expression of p21WAF1 is an indicator of malignant behaviour in anal carcinomas. Histopathology. July 2001;39(1):43–49.
et al. Sphincter preservation with chemoradiation in anal canal carcinoma: abdominoperineal resection in selected cases? Dis Colon Rectum. April 1998;41(4):441–450.
et al. Epidermal growth factor receptor expression as prognostic marker in patients with anal carcinoma treated with concurrent chemoradiation therapy. Int J Radiat Oncol Biol Phys. August 1, 2013;86(5):901–907.
et al. A novel biomarker-based analysis reliably predicts nodal metastases in anal carcinoma: preliminary evidence of therapeutic impact. Colorectal Dis. November 2013;15(11):1382–1391.
MJ. Epidermal growth factor receptor expression in anal canal carcinoma. Am J Clin Pathol. July 2005;124(1):20–23.
et al. EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer. Histol Histopathol. October 14, 2013.
et al. EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?
Br J Cancer. November 20, 2012;107(11):1864–1868.
et al. Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus
and human immunodeficiency virus. Hum Pathol
. November 2009;40(11):1517–1527.
G. K-ras status in squamous cell anal carcinoma (SCC): it’s time for target-oriented treatment?
Cancer Chemother Pharmacol
. December 2009;65(1):197–199.
et al. Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Ann Oncol. November 2013;24(11):2834–2838.
et al. Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. Cancer. August 15, 2013;119(16):2973–2980.
LA. Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): safety and preliminary efficacy results [Abstract].
J Clin Oncol. 2012;30(suppl 15):Abstract 4030.
WJ. Management of carcinoma of anal canal. Surgery. October 1981;90(4):729–734.
A. Malignant epithelial tumors of the anal canal. Cancer. July 15, 1981;48(2):411–415.
M. Accuracy of endoanal ultrasound in the follow-up assessment for squamous cell carcinoma of the anal canal treated with radiochemotherapy. Surg Endosc. September 24, 2008.
A. Endoanal ultrasound evaluation of anorectal diseases and disorders: technique, indications, results and limitations. Eur J Radiol. March 2007;61(3):480–489.
HR. The National Cancer Data Base report on carcinoma of the anus. Cancer. August 15, 1997;80(4):805–815.
et al. NCCN clinical practice guidelines in oncology. Anal carcinoma. J Natl Compr Canc Netw. January 2010;8(1):106–120.
JH. Positron emission tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol. July–August 2005;7(4):309–313.
et al. FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys
et al. Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol
PW. Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. Radiother Oncol
et al. Metabolic tumor volume predicts disease progression and survival in patients with squamous cell carcinoma of the anal canal. J Nucl Med
JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA[JAMA and JAMA Network Journals Full Text]
. May 19, 1999;281(19):1822–1829.
CS. Anal cancer and screening guidelines for human papillomavirus
in men. J Am Osteopath Assoc
. March 2011;111(3 suppl 2):S35–S43.
JM. Screening for anal and cervical dysplasia in HIV-infected patients. PRN Notebook. 2001;6(3):24–31.
ML. High-resolution anoscopy in the planned staged treatment of anal squamous intraepithelial lesions in HIV-negative patients. J Gastrointest Surg. November 2007;11(11):1410–1415; discussion 1415–1416.
ML. High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum
. June 2008;51(6):829–835; discussion 835–827.
et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol. December 2007;157(suppl 2):25–31.
et al. Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. Arch Dermatol[Archives of Dermatology Full Text]
. November 2006;142(11):1438–1444.
U, de Vries
et al. Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men. Br J Dermatol. December 2010;163(6):1301–1307.
et al. Polyphenon E: a new treatment for external anogenital warts. Br J Dermatol. January 2010;162(1):176–184.
O, de Vries
HJ, van Noesel
JM. Comparison of imiquimod, topical fluorouracil
, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. Lancet Oncol
. April 2013;14(4):346–353.
EL. Long-term outcome of ablation of anal high-grade squamous intraepithelial lesions: recurrence and incidence of cancer. Dis Colon Rectum. March 2014;57(3):316–323.
SE. Long-term follow-up of infrared coagulator ablation of anal high-grade dysplasia in men who have sex with men. Dis Colon Rectum. October 2011;54(10):1284–1292.
Jr. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum
JJ. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer
et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol
UKCCCR Anal Cancer Trial Working Party. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin
. Lancet. 1996;348(9034):1049–1054.
et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer
et al. Role of mitomycin
in combination with fluorouracil
and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol
. September 1996;14(9):2527–2539.
et al. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol
et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil
/cisplatin. J Clin Oncol
et al. Mitomycin
or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol
et al. Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients. Cancer
et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys
et al. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys
J. An interactive digital computer system for radiotherapy treatment planning. Br J Radiol
WF. External beam treatment-planning with the programmed console. Radiology
W. Results and toxicity of the treatment of anal canal carcinoma by radiation therapy or radiation therapy and chemotherapy. Cancer
AS, Ten Haken
RK. Three-dimensional treatment planning and conformal radiation dose delivery. Important Adv Oncol. 1995:95–109.
BA. The development of conformal radiation therapy. Med Phys
. 1995;22(11 pt 2):1911–1921.
ML. Computer-controlled treatment delivery. Semin Radiat Oncol
et al. Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy. Int J Radiat Oncol Biol Phys
JA. 3D treatment planning and intensity-modulated radiation therapy. Oncology
. 1999;13(10 suppl 5):155–168.
LJ. Comparison of three-dimensional conformal radiation therapy and intensity-modulated radiation therapy systems. Semin Radiat Oncol
Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys
et al. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys
A, Van Rooij
PC. Toxicity and outcome of intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy for oropharyngeal cancer: a matched-pair analysis. Technol Cancer Res Treat
et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys
JR. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol
et al. Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes. Int J Radiat Oncol Biol Phys
SJ. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys
et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol
et al. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer
et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. May 1, 2013;86(1):27–33.
MC, El Naqa
et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys
et al. Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys
et al. Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys
et al. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. December 1, 2013;87(5):983–991.
J. Long-term recovery of spermatogenesis after radiotherapy in patients with testicular cancer. Radiother Oncol
et al. Testicular dose and hormonal changes after radiotherapy of rectal cancer. Radiother Oncol
T. Cancer, fertility preservation, and future pregnancy: a comprehensive review. Obstet Gynecol Int. 2012;953937(10):18.
et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol
NP. Laparoscopic oophoropexy and ovarian function in the treatment of Hodgkin disease. Cancer
H. Needle oophoropexy: a new simple technique for ovarian transposition prior to pelvic irradiation. Surg Endosc
SE. Sexual function in colorectal cancer survivors. Cancer Control
et al. Risk factors for sexual dysfunction after rectal cancer treatment. Eur J Cancer
et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med
EJ. Interventions for the physical aspects of sexual dysfunction in women following pelvic radiotherapy. Cochrane Database Syst Rev. 2003;1:CD003750.
et al. Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. Acta Oncol
IN. The natural history of radiation-induced proctosigmoiditis: an analysis of 88 patients. Q J Med
NP. Management of radiation proctitis. Am J Clin Oncol. 2013;11:11.
KN. Argon laser therapy for hemorrhagic radiation proctitis: long-term results. Gastrointest Endosc
MA. Formalin instillation for ischemic proctitis with unrelenting hemorrhage: report of a case. Dis Colon Rectum
et al. Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomized and controlled double-blind crossover trial with long-term follow-up. Int J Radiat Oncol Biol Phys
Y. Functional disorders after rectal cancer resection: does a rehabilitation programme improve anal continence and quality of life?
CM. Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease. Dis Colon Rectum. April 2014;57(4):423–431.
R. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys. April 1, 1999;44(1):127–131.
et al. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. Dis Colon Rectum. January 2008;51(1):73–81.
Jr. Management of anal cancer in the HIV-positive population. Oncology. November 2005;19(12):1634–1638; discussion 1638–1640, 1645 passim.
et al. Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin
(MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: results of ACT II. J Clin Oncol
. 2012;(suppl):abstract 4004.
PW. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys
et al. Anal canal cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. July 2005;3(4):510–515.
et al. Squamous cell carcinoma antigen as a marker for squamous cell carcinoma of the anal canal. J Clin Oncol
. May 1988;6(5):782–785.
et al. Squamous cell carcinoma antigen: a potentially useful prognostic marker in squamous cell carcinoma of the anal canal and margin. Cancer. July 1 2013;119(13):2391–2398.
et al. Assessment of “squamous cell carcinoma antigen” (SCC) as a marker of epidermoid carcinoma of the anal canal. Dis Colon Rectum. February 1991;34(2):126–131.
A. The utility of squamous cell carcinoma antigen for the follow-up of patients with squamous cell carcinoma of the anal canal. Cancer. July 1, 1992;70(1):35–39.
et al. Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy. Dis Colon Rectum. July 2004;47(7):1136–1144.
SH. Salvage abdominoperineal resection following combined chemotherapy and radiotherapy for epidermoid carcinoma of the anus. Ann Surg Oncol. March 1994;1(2):105–110.
FE. Recurrent squamous cell carcinoma of the anal canal. Predictors of initial treatment failure and results of salvage therapy. Ann Surg. July 1994;220(1):40–49.
et al. Abdominoperineal resection for squamous cell anal carcinoma: survival and risk factors for recurrence. An Surg Oncol. December 2012;19(13):4186–4192.
et al. Salvage abdominoperineal resection for anal cancer following chemoradiation: a proposed scoring system for predicting postoperative survival. J Surg Oncol. April 2013;107(5):486–492.
T. Salvage surgery for residual primary and locally recurrent anal squamous cell carcinoma after chemoradiotherapy in HIV-positive individuals. Ann Surg Oncol
. February 2014;21(2):527–532.
et al. Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors?
J Gastrointest Surg. December 2007;11(12):1744–1751.
R. Risk factors for perineal wound complications following abdominoperineal resection. Dis Colon Rectum. January 2005;48(1):43–48.
S. Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap. Ann Surg Oncol. January 2009;16(1):68–77.
H. Use of transpelvic rectus abdominis musculocutaneous flap for anal cancer salvage surgery. Br J Surg
. May 2003;90(5):575–580.
J. Definitive combined modality therapy of carcinoma of the anus. A report of 30 cases including results of salvage therapy in patients with residual disease. Dis Colon Rectum. July 1987;30(7):495–502.
JJ. Inguinal lymph node recurrence in the untreated groin of patients with anal carcinoma. Dis Colon Rectum
. May 2014;57(5):578–584.
BJ. Metastatic anal cancer: the search for cure. Onkologie. February 2006;29(1–2):5–6.
S. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med
R. Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. Am J Clin Oncol
et al. DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. Ann Oncol
et al. Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. Ann Surg Oncol. October 2007;14(10):2807–2816.
et al. Conservative treatment by irradiation of epidermoid cancers of the anal canal: prognostic factors of tumoral control and complications. Int J Radiat Oncol Biol Phys. January 15, 1997;37(2):313–324.
et al. The role of local therapy in the management of lung and liver oligometastases. Nat Rev Clin Oncol
et al. Refined staging by sentinel lymph node biopsy to individualize therapy in anal cancer. Ann Surg Oncol. March 2004;11(3 suppl):259S–262S.
JC, van Dam
T. Limited value of staging squamous cell carcinoma of the anal margin and canal using the sentinel lymph node procedure: a prospective study with long-term follow-up. Ann Surg Oncol. October 2010;17(10):2656–2662.
ER. Quadrivalent human papillomavirus
vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep
. March 23, 2007;56(RR-2):1–24.
FDA licensure of quadrivalent human papillomavirus
vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep
. May 28, 2010;59(20):630–632.
et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. October 27, 2011;365(17):1576–1585.
FDA licensure of bivalent human papillomavirus
vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep
. May 28, 2010;59(20):626–629.
et al. Comprehensive control of human papillomavirus
infections and related diseases. Vaccine
. November 22, 2013;31(suppl 8):I1–I31.
National and state vaccination coverage among adolescents aged 13-17 years—United States, 2012. MMWR Morb Mortal Wkly Rep. August 30, 2013;62(34):685–693.
II. The role of human papilloma virus (HPV) vaccination in the prevention of anal cancer in individuals with human immunodeficiency virus-1 (HIV-1) infection. Ther Adv Vaccines. July 2013;1(2):81–92.
et al. Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus
vaccine to HIV-infected children. J Infect Dis
. October 2012;206(8):1309–1318.
et al. Safety and immunogenicity of the quadrivalent human papillomavirus
vaccine in HIV-1-infected men. J Infect Dis
. October 15, 2010;202(8):1246–1253.
et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus
vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis
. April 15, 2014;209(8):1165–1173.
et al. Human papillomavirus
genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men. J Infect Dis
. February 1, 2013;207(3):392–401.
et al. Time to consider HPV vaccination after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. August 2010;16(8):1033–1036.
A. Immunogenicity of quadrivalent human papillomavirus
vaccine in organ transplant recipients. Am J Transplant
. September 2013;13(9):2411–2417.